Lung Cancer
Volume 45, Supplement , Pages S49-S54, August 2004

Prognostic factors in malignant mesothelioma

  • Jacobus A Burgers

      Affiliations

    • Department of Thoracic Oncology, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31-20-5122958; fax: +31-20-5122572.
  • ,
  • Ronald A.M Damhuis

      Affiliations

    • Rotterdam Cancer Registry, Rotterdam, The Netherlands

Abstract 

Many prognostic factors have been described in malignant mesothelioma, but only a limited number has been validated by prospective, confirmatory studies. These include performance status, histology, weight loss and leucocyte count. Their value as predictors of patient survival in malignant mesothelioma is limited, as is their role in current clinical practice. At this moment their main importance is their application in clinical studies, which allows a better delineation of the patient group to which the study results can be applied to and a more accurate comparison between different studies. The biological prognostic factors need confirmation by larger prospective trials and should be analysed with respect to the existing prognostic factors. In the future, their use might not be limited to the prediction of the patient survival but direct the development of new therapies and extend to the molecular prediction of tumour response.

Keywords:  Prognostic factors, Performance status, Prognostic scoring systems, Anatomical staging, Biological markers, Mesothelioma

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0169-5002(04)00172-2

doi:10.1016/j.lungcan.2004.04.012

Lung Cancer
Volume 45, Supplement , Pages S49-S54, August 2004